代谢功能障碍相关的脂肪性肝病的临床前模型用于治疗测试
Alissa M Cutrone1,2,3, Heidi Yeh1, Korkut Uygun2,3
11Center for Transplantation Sciences, Massachusetts General Hospital, Boston, Massachusetts, USA.
Annual review of biomedical engineering
|February 5, 2026
概括
与代谢功能障碍相关的脂肪性肝病 (MASLD) 影响全球许多人. 本综述详细介绍了研究MASLD的临床前模型,强调了标准化,以推进肝病药物发现.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 临床前研究 临床前研究
- 药物发现 药物发现 药物发现
背景情况:
- 与代谢功能障碍相关的脂肪性肝病 (MASLD) 是一种普遍存在的肝病.
- MASLD可能会发展为严重的肝损伤,如肝硬化和末期肝病.
- 有效的临床前模型对于理解MASLD和开发治疗方法至关重要.
研究的目的:
- 为研究MASLD提供当前技术的全面概述.
- 突出模型标准化在MASLD研究中的重要性.
- 为了促进MASLD的加速药物发现.
主要方法:
- 对MASLD的体外,外生和体内临床前模型的审查.
- 在疾病驱动因素,物种和生物复杂性方面分析模型多样性.
- 专注于MASLD研究中的技术进步.
主要成果:
- 存在各种各样的临床前模型,从细胞系统到整个生物体.
- 这些模型提供了明显的优势,但在模拟MASLD的方法上有很大差异.
- 跨模型的疾病进展标准化是一个关键的挑战和机会.
结论:
- 多种临床前模型可用于MASLD研究.
- 标准化这些模型对于一致的结果和有效的治疗开发至关重要.
- 推进MASLD研究需要对临床前建模采取统一的方法.
相关概念视频
Diseases of the Liver and Gallbladder
2.0K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.0K
What is Metabolism?
132.0K
Overview
132.0K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
206
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
206
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
234
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234
Therapeutic Index
6.9K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.9K
Preclinical Development: Overview
6.0K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.0K


